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KEY POINTS
 Split-dose bowel regimens should be used in patients without increased risk for gastric
retention or aspiration.
 Excessive prepreparation dietary restriction may worsen patient tolerability and prepara-
tion quality.
 Patient education enhances patient compliance and bowel preparation quality.INTRODUCTION
Patientswith inflammatory bowel disease (IBD) are at increased risk of developing colo-
rectal cancer.Comparedwith sporadic cases, IBD-related colorectal cancers occur at a
younger age,1 aremore likely multifocal or synchronous,2,3 and have amore aggressive
phenotypewith worsenedmortality.3,4 In light of the increased risk of colorectal cancer,
regular colonoscopy is advised every 1 to 3 years in patients for surveillance of colo-
rectal neoplasia. Candidates for surveillance are those with disease duration of 8 years
or more who have either ulcerative colitis extending beyond the rectum or Crohn’s dis-
ease involving one-third or more of the colon. Strong, albeit indirect, data5–8 suggest a
benefit to colonoscopic surveillance. It is therefore recommended by numerous profes-
sional guidelines9–12 and has become widely adopted in standard practice.
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The purpose of surveillance colonoscopy in IBD is to detect neoplasia (ie, cancer or
precancerous dysplasia). Until recently, common surveillance technique has entailed
a combination of targeted and random biopsies. All visible lesions receive targeted bi-
opsy or resection (via polypectomy or endoscopic mucosal resection) to determine the
histology and, most especially, the presence of dysplasia or cancer. In addition, by US
guidelines, at least 33 additional random biopsies are taken throughout the colon to
detect the presence of flat, endoscopically invisible dysplasia. However, with the
advent of enhanced endoscopic imaging, it is increasingly recognized that most
IBD-related dysplasia is visible with careful mucosal inspection using high-definition
endoscopes and chromoendoscopy. In chromoendoscopy, a solution containing
dilute indigo carmine or methylene blue is applied to the mucosal surface via the for-
ward wash jet or biopsy channel to enhance lesion detection (Fig. 1). Augmented
lesion recognition via chromoendoscopy may supplant the need for random biopsy.
A meta-analysis by Soetikno and colleagues13 confirmed that chromoendoscopy
with targeted biopsies of visualized lesions resulted in increased dysplasia detection
rates compared with standard white light endoscopy and random biopsies. Several
guidelines12,14,15 now endorse the routine use of chromoendoscopy and question
any incremental benefit of random biopsies to detect invisible dysplasia.
This shift in surveillance practice toward targeted lesion biopsy (with endoscopic
resection if possible) relies on the premise that even subtle dysplastic lesions are
detectable with enhanced imaging techniques. Consequently, a meticulous bowel
preparation is critical to facilitate detection of nonpolypoid (flat, slightly raised, orFig. 1. (A) Poor bowel preparation preventing mucosal visualization. (B) Concealed lesion
shown after irrigation and suctioning. (C) Lesion visualization enhanced by chromoendo-
scopy dye application. (Courtesy of Silvia Sanduleanu, MD, PhD, Maastricht University, Maas-
tricht, The Netherlands.)
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fecal matter, succus, or purgative solution (Fig. 2). Although studies have not specif-
ically examined the impact of inadequate bowel preparation on IBD surveillance out-
comes, there is clear evidence in the general population that inadequate preparation
negatively affects outcomes of screening or surveillance colonoscopy and increases
resource use. Bowel preparation is inadequate in nearly 1 of 4 colonoscopies.16,17
Furthermore, suboptimal preparation results in aborted or incomplete examinations
in up to 7% of cases and leads to early recall for surveillance in 12.5% to 20% of
cases.18 Suboptimal preparation also negatively affects colonoscopy efficiency, being
associated with prolonged cecal intubation times, decreased cecal intubation rates,
increased withdrawal time, and increased perceived procedural difficulty.19
Most importantly, suboptimal bowel preparation is associated with lower polyp
detection rates, affecting detection of flat (nonpolypoid) lesions20 and small polyps,16
as well as large polyps (>10mm).19 Among patients undergoing colonoscopy less than
3 years after a previous examination with suboptimal bowel preparation, 42% of all
adenomas and 27% of advanced adenomas were found only after the repeat exam-
ination. Among examinations performed within 1 year of the initial suboptimal exam-
ination, the advanced adenoma miss rate was 36%, suggesting these lesions were
truly missed.17 In another series of 133 patients undergoing repeat colonoscopy after
previous suboptimal preparation, missed adenomas were found in 34%. A high-risk
state was present in 18% of patients (ie, the presence of 3 adenomas, 1
adenoma >1 cm, or adenomas with high-grade dysplasia or villous features).21 Simi-
larly, Sagi and colleagues22 reported that among patients undergoing early examina-
tion as a result of initial suboptimal bowel preparation, 6.5% had high-risk adenomas
and 1.9% had high-grade dysplasia or cancer.
It is evident from the literature that inadequate preparation negatively affects the
performance of colonoscopy in patients who do not have IBD. Although not directlyFig. 2. Feculentmaterial obscuring visualization of nonpolypoid lesions in (A, B) Crohn’s colitis
and (C, D) ulcerative colitis. (Courtesy of Roy Soetikno, MD, Veterans Affairs, Palo Alto, CA.)
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facilitates detection of IBD-related neoplasia, particularly nonpolypoid lesions. Flat
dysplasia detection in patients with IBD has been shown to be directly correlated
with procedure duration.23 Although the underlying reason for this association is un-
proven, prolonged withdrawal may reflect careful mucosal inspection. Poor prepara-
tion requiring lengthy irrigation may lessen total inspection time.
An impeccable bowel preparation is especially important for chromoendoscopy
surveillance techniques.24 Personal and anecdotal shared experiences affirm the
negative impact of suboptimal bowel preparation on the efficient application of chro-
moendoscopy. The admixture of chromoendoscopy dye with retained colonic soilage
results in flocculent, green debris, which can obscure subtle lesions and require
copious irrigation to achieve an acceptable mucosal inspection (Fig. 3).
PREDICTORS OF SUBOPTIMAL BOWEL PREPARATION
In patients without IBD, the known predictors of poor bowel preparation include
advanced age, male gender, diabetes, obesity, multiple comorbidities, tricyclic anti-
depressant or opiate use, inpatient status, immobility, and lower education level.25–27
Most studies examining risk factors for poor colonic preparation do not assess the
impact of IBD.25 When specifically evaluated, no significant difference in bowel prep-
aration quality was detected between patients with IBD and those who did not have
IBD, as rated by the Boston Bowel Preparation Scale. Nor did an association exist be-
tween IBD disease activity and preparation quality.28 Thus, there is no definitive proof
that patients with IBD have an increased likelihood of inadequate bowel preparation.
Notwithstanding this limited published experience, personal and anecdotal experi-
ence suggests increased difficulty with bowel preparation in some patients with IBD.
Bowel preparation is of poorer quality in patients with previous colonic resections,29,30
including patients with and without IBD, possibly because of disturbances in intestinal
motility. Furthermore, some patients with IBD have increased nausea, bloating,
cramping, or vomiting as a result of previous surgery, intestinal stenosis, altered
motility, anxiety, or heightened visceral sensitivity. In a case control study by Bessis-
sow and colleagues,28 patients with IBD did not experience increased levels of nausea
or pain during bowel preparation overall, but patients with active Crohn’s disease didFig. 3. Poor preparation interferes with chromoendoscopy. Admixture of stool, dye, and
mucus interferes with mucosal visualization. (Courtesy of Roy Soetikno, MD, Veterans
Affairs, Palo Alto, CA.)
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ated with increased symptoms during bowel preparation, and patients with IBD expe-
rience significantly more embarrassment and burden (defined as feelings of worry,
hardship, or distress) during preparation when compared with patients undergoing
colonoscopy for other indications.31 Furthermore, in a study assessing factors
affecting adherence with surveillance recommendations,32 patients with IBD most
commonly cited difficulty with bowel preparation as the most important reason for
failed compliance. Thus, although limited clinical studies do not convincingly show
a higher incidence of suboptimal bowel preparations in patients with IBD, ample
data confirm a reduced tolerance of the bowel preparation, which may negatively
affect bowel preparation quality and compliance with surveillance protocols.OPTIMIZATION OF BOWEL PREPARATION
Bowel Preparation in Patients with Active Inflammation
Optimization of the preparation protocol helps to promote thorough colonic prepara-
tion and maximize surveillance benefit. The best strategy for preparation in patients
with IBDmay vary depending on the indication for colonoscopy. In patients with active
symptoms undergoing endoscopy to assess the activity and extent of disease, con-
siderations include the potential complications of aggressive bowel preparation in
the context of active inflammation. For example, partial obstruction caused by fixed
or inflammatory strictures, delayed gastric emptying (medication or disease-
related), hospitalization status, and urgency of the examination may all affect the
bowel preparation regimen, including the choice of purgative, and the frequency,
rate, and mode of purgative delivery. Concern for partial or high-grade obstruction
may favor the use of small-volume, oral solutions supplemented by intravenous hydra-
tion or the use of a slow oral trickle preparation delivered over longer periods rather
than more rapid administration of large-volume solutions. Furthermore, use of split-
dosing regimens (which include same-day purgative administration 4–6 hours before
endoscopy) may be contraindicated in the setting of mechanically delayed intestinal
transit because of higher aspiration risk. Patients with severe active colitis and diar-
rhea may require only minimal laxative administration to achieve adequate preparation
for disease staging because of rapid transit, the absence of solid fecal matter, and
decreased adherence of liquid stool to the intestinal wall. British National Health Ser-
vice guidelines33 designate severe acute active inflammation as an absolute contrain-
dication to oral preparation administration. Thus, in patients with active disease, safety
factors and disease-related symptoms make a pristine colon a less rigid goal of bowel
preparation.
Bowel Preparation in Patients Undergoing Surveillance
In contrast, a meticulous bowel preparation is important in patients undergoing
routine, elective colonoscopy for dysplasia surveillance. Whenever possible, the dis-
ease should be in remission at the time of surveillance colonoscopy, because active
inflammation interferes with visual detection of nonpolypoid dysplasia and causes
cytologic changes, which can be difficult to distinguish from true dysplasia. Complica-
tions of active inflammation therefore are of lesser concern, and preparation decisions
focus on achieving maximum bowel cleanliness.
The best preparation regimen consists of an appropriate preprocedure diet, a suit-
able choice of laxative agent, and an optimal dosing of laxative administration. It is
vitally important that physicians and nursing staff educate patients about the impor-
tance of the bowel preparation, carefully reviewing recommended dietary restrictions
Nett et al384and counseling strict adherence to bowel preparation instructions. The remainder of
this article emphasizes recommended, established preparation techniques for the
purpose of nonurgent surveillance in patients with controlled disease.
Prepreparation dietary restriction
There are several uncertainties regarding thebest preprocedurediet. In thedays leading
up to colonoscopy,many centers advise patients to avoid foods containing small seeds
(eg, tomatoes and cucumbers) based on concern that colonoscopy efficiency can be
diminished by clogging of the endoscope suction channel. This problem does arise,
especially among patients with diverticulosis, although there is no literature studying
the degree of encumbrance. Other routine advice includes several days of avoidance
of high-fiber food or supplements, especially iron-containing supplements,which cause
blackening of stool with increased adhesion of remnant stool to the bowel wall.
On the day preceding colonoscopy, patients are routinely instructed to consume
only clear liquids. Many centers also advise patients to forego red-colored food prod-
ucts such as red gelatin, red juices, or red soft drinks to avoid confusion regarding the
presence of possible blood. However, the rate of false alarm caused by these prod-
ucts has not been studied, and anecdotal experience suggests that their consumption
is unlikely to create diagnostic uncertainty with the use of proven high-quality bowel
preparation regimens.
Several recent studies have suggested that rigid adherence to a clear liquid diet on
the day preceding the procedure may also be unnecessary (Table 1). Dietary liber-
alization may allow for improved tolerance and better adherence without compromise
of bowel preparation quality.34 In some studies, a less restrictive diet increases bowel
preparation quality.35–37
Frequency and timing of bowel laxative preparations: importance of split regimens
The most critical component of bowel preparation is the use of an appropriate laxative
regimen. Regardless of the type of laxative prescribed (Table 2), there is over-
whelming evidence from randomized controlled trials supporting of the use of split-
dosing regimens. In these regimens, partial laxative administration occurs on the
evening before colonoscopy, with the remainder administered within 2 to 6 hours
before colonoscopy. A meta-analysis performed by Kilgore and colleagues38 of 5 ran-
domized controlled trials showed that, compared with single, full-dose administration
of 4 L polyethylene glycol (PEG) solution on the evening before the procedure, the
administration of split-dose PEG preparations (2 L the evening before the procedure
and 2 L completed by 2 hours before the procedure) resulted in a higher likelihood
of satisfactory bowel preparations (odds ratio [OR] 3.7; 95% confidence interval [CI]
2.79–4.41), an increased willingness to repeat the same preparation, and decreased
nausea. Another systematic review by Enestvedt and colleagues39 of 9 trials
comparing 4 L split-dose PEG preparations with various other bowel preparation reg-
imens (4 L single dose or smaller volume split dose) confirmed a significantly higher
likelihood of excellent or good bowel preparation with the 4 L split-dose regimen
(OR 3.46; 95% CI 2.45–4.89). No difference existed between the 4-L split-dose PEG
formulations and alternative preparations in regards to patient compliance, willingness
to repeat preparation, overall experience, or symptoms of abdominal cramping,
nausea, or sleep disturbance. A recent study has confirmed that use of a split-dose
3-L PEG/ascorbic acid preparation (2 L PM, 1 L AM) not only improved bowel prepara-
tion quality but also was associated with increased adenoma detection rates.40 Based
on the proven superiority of split-dose bowel regimens over single-dose regimens,
professional guidelines41,42 now recommend use of split-dose preparation.
Table 1
Effect of less restrictive prepreparation diet on bowel preparation quality and tolerability
Study N
Prepreparation Diet
Bowel Preparation Dosing
Bowel Preparation
Quality
Better Patient
TolerabilityDiets Compared
Duration of Dietary
Liberalizationa
Soweid et al,35 2010 200 Fiber free vs clear liquid Entire day 4 L PEG-ELS Single Fiber free > clear
liquid
Fiber free
Park et al,36 2009 214 Low residue vs clear liquid Entire day 4 L PEG-ELS Single Low residue > clear
liquid
Low residue
Melicharkova et al, 2013 213 Low residue vs clear liquid Breakfast Na picosulfate/
magnesium citrate
Single No difference Low residue
Sipe et al,34 2013 196 Low residue vs clear liquid Breakfast 1 lunch 1
snack
Sulfate solution Split No difference Low residue
Jung et al,56 2013 801 Regularb vs clear liquid Entire day 4 L PEG-ELS Single No difference No difference
a Portion of the day before colonoscopy in which 1 group in comparative trial was allowed a diet less restrictive than clear liquids.
b Although groups were assigned to either regular intake or a clear liquid diet on the day before colonoscopy, patients in both groups were advised to avoid high-
fiber foods in the 3 days before colonoscopy.56
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Table 2
Laxative options for bowel preparation
Type
Total
Volume
Product
Name
FDA-Approved
Dosing
Split Dosing
Reported?
Isosmotic
Standard PEG-ELS 4 L GoLytely
Colyte
Generic
Single day Yes
Sulfate-free PEG-ELS 4 L NuLytely
TriLyte
Single day Yes
Sulfate-free PEG-ELS 1 preceding
bisacodyl
2 L HalfLytely Single day No
PEG-ELS with ascorbate 3 L MoviPrep Single day or split Yes
Gatorade 1 Miralax 238 g 2 L Gatorade 1
Miralax
Not FDA approved Yes
Hyperosmotic
Sodium/potassium/magnesium
sulfate and PEG-ELS
3.5 L Suclear Single day or split Yes
Sulfate solution (sodium sulfate,
potassium sulfate, magnesium
sulfate)
3 L Suprep Split Yes
Sodium picosulfate, magnesium
oxide, citrate
2.2 L Prepopik Single day or split Yes
Sodium phosphate tablets 2 L OsmoPrep Split Yes
Abbreviations: ELS, electrolyte lavage solution; FDA, US Food and Drug Administration; PEG, poly-
ethylene glycol.
Nett et al386Morning consumption of laxative as part of a split-dose regimen creates 2 concerns.
First, patients may be resistant to waking early to complete the laxative. Despite this
pragmatic consideration, patients do generally accept and comply with split dosing.
Unger and colleagues43 reported 78% compliance with a split dose in patients
receiving early morning colonoscopy. Several studies44,45 have also shown that pa-
tients better tolerate split-dosing preparations.
The second concern pertains to the safety of split-dosing administration. Specif-
ically, ingestion of the second dose of a bowel laxative within 2 to 6 hours of colonos-
copy might increase the risk for aspiration during sedation (moderate, deep, or general
anesthesia). Updated guidelines from the American Society of Anesthesiologists46
state that patients need to abstain from clear liquids for only 2 hours before receiving
sedation. Nonetheless, some anesthesiologists question the clinical and safety equiv-
alency of PEG solutions to other clear liquids. In addressing these concerns, despite
widespread use of PEG solutions for almost 30 years in millions of patients, there are
only rare (<12), isolated reports of fatal, aspiration-induced chemical pneumonitis after
administration of a PEG solution (most commonly occurring with nasogastric admin-
istration in adults or children with altered mental status). Furthermore, a 2010 study47
showed no difference in residual gastric volume in patients taking a split-dose bowel
preparation (19.7 mL) versus a single-dose evening preparation (20.2 mL).
Therefore, based on their proven superiority, split-dose bowel regimens should be
recommended for most patients with IBD undergoing surveillance whose disease is in
remission or well controlled. Caution is advised in patients with partial bowel obstruc-
tion, gastroparesis, or known delayed intestinal motility, because these patients are at
Quality Bowel Preparation in Patients with IBD 387increased risk for gastric retention and aspiration. In these instances, a 6-hour window
is recommended between completion of the laxative ingestion and initiation of
sedation.
Available preparation formulations: how to choose
Several laxative formulations are available for preparation before colonoscopy. Ran-
domized controlled trials comparing these agents are limited, and none has proven su-
periority. However, for all available agents, a split-dose regimen generally is preferred
to single-dose regimens.
Laxative options may be subsumed under 2 broad categories: PEG solutions and
low-volume, hyperosmolar solutions (see Table 2). Several PEG solutions are avail-
able, including full-volume (4 L) balanced, isosmotic formulations (standard or
sulfate-free) and a reduced volume (3 L) formulation, which contains ascorbate. In
general, split dosing of PEG solutions achieves good or excellent bowel preparation
quality in 75% to 95% of patients compared with less than 60% with single-dose
administration. Although some endoscopy centers recommend the use of a split-
dose administration of a 2-L homemade solution of Gatorade plus PEG-3350 (Miralax),
a meta-analysis has found this regimen to be inferior to standard, split-dose 4-L PEG
solutions.39
Two low-volume hyperosmolar solutions that do not contain PEG are available, but
both must be taken with sufficient amounts of water to promote adequate cleansing.
These solutions include a sulfate solution (Suprep, 3 L, including water) and a magne-
sium citrate/picosulfate solution (Prepopik, 2.2 L, including water). Because these
hyperosmolar solutions may cause dehydration and electrolyte shifts, they should
be used with caution in patients with significant renal or cardiac disease or in patients
unable or unlikely to comply with instructions. There are no controlled trials comparing
split dosing of low-volume, hyperosmolar solutions and split dosing of standard large-
volume 4-L PEG solutions, and hence, it is unknown whether these low-volume
options provide comparable outcomes. A trial48 comparing split dosing of a low-
volume sulfate-based preparation with split dosing of a low-volume (2 L) PEG solution
containing ascorbic acid (MoviPrep) yielded a comparable proportion of good or
excellent preparations.
Most recently, another preparation (Suclear) has become available, in which a sul-
fate solution (1 L, including water) is administered the evening before the procedure,
and balanced PEG solution (2 L) is administered 4 hours before the procedure. In a
controlled trial, split dosing of the sulfate/PEG formulation achieved a similar level of
acceptable bowel preparation as split dosing of a low-volume (2 L) PEG/ascorbic
acid solution.49 Phosphate-based preparations (tablets and solutions) are still avail-
able but have significant potential for adverse consequences. These preparations
can induce mucosal ulcerations that mimic IBD, confusing disease diagnosis and
staging. More importantly, several reported cases of severe hyperphosphatemia
have occurred (some complicated by mortality) as well as cases of acute phosphate
nephropathy. Because of safety concerns as well as the availability of numerous alter-
native preparation options, phosphate-based solutions should be avoided.50
No studies have compared specific preparation types in patients with IBD. Thus,
physicians and endoscopy centers may favor particular agents based on personal
experience, reported patient satisfaction, and cost considerations. Based on the
extensive body of literature supporting their efficacy and safety, bowel regimens
with a split-dose of a full-volume (4 L) balanced PEG solution may be recommended
for most patients. The European Society of Gastrointestinal Endoscopy51 specifically
recommends use of a PEG formulation in patients with IBD, because alternative
Fig. 4. Sample images from educational pamphlet shown to enhance preparation quality.
(From Spiegel BM, Talley J, Shekelle P, et al. Development and validation of a novel patient
educational booklet to enhance colonoscopy preparation. Am J Gastroenterol 2011;106(5):
875–83; with permission.)
Nett et al388formulations can cause mucosal damage. However, as noted earlier, patients with IBD
commonly cite difficulty with bowel preparation as a reason for nonadherence to a
surveillance program. Thus, in patients with previous intolerance of large-volume
preparations or in whom intolerance is anticipated because of heightened anxiety,
low-volume alternatives should be considered to improve compliance, provided there
are no contraindications to these agents (renal, cardiac, or liver disease).
Patient Education
Patient education may enhance bowel preparation quality by promoting adherence to
the preparation regimen. Rosenfeld and colleagues52 showed that inpatients receiving
a 5-minute educational talk regarding the reason for bowel preparation and the impor-
tance of preparation completion had improved preparation quality. Likewise, in a
controlled trial of 436 patients, the patients randomized to receive an educational
booklet had improved satisfactory bowel preparation quality (76%) compared with
those not receiving a booklet (46%).53 Clear visual references show patients specific
end points of colonic preparation (Fig. 4). Other studies also have confirmed the use-
fulness of cartoon visual aids54 and educational pamphlets55 in promoting improved
bowel preparation quality.SUMMARY
IBD surveillance mandates scrupulous bowel preparation to optimize detection of
nonpolypoid dysplasia. Split-dose administration of a PEG-based regimen is recom-
mended in patients without contraindications. Some patients with IBD may have
reduced tolerance of bowel preparation. Low-volume preparations should be consid-
ered in patients with known stenosis, dysmotility, anxiety, active disease, or previous
preparation intolerance to promote adherence to surveillance protocols. Avoidance of
Quality Bowel Preparation in Patients with IBD 389unnecessary dietary restriction and provision of thorough patient education also
enhance patient tolerance and compliance.REFERENCES
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